NCT07264569 2025-12-04
Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001
Henan Cancer Hospital
Phase 1/2 Recruiting
Clinical Trials
6 trialsNCT06971406 2025-05-14
FLAME-1
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT06643000 2025-03-06
Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis
Henan Cancer Hospital
Phase NA Recruiting
NCT06441045 2024-06-04
Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT05805631 2024-05-01
Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC
Taipei Veterans General Hospital, Taiwan
Phase 2 Not yet recruiting
NCT04778800 2021-08-31
A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)
Henan Cancer Hospital
Phase NA Unknown